Loughborough University
Browse
Diabetes weight loss therapies and PA_R1_Clean.pdf (393.23 kB)

Initiation of new glucose-lowering therapies may act to reduce physical activity levels: pooled analysis from three randomized trials

Download (393.23 kB)
journal contribution
posted on 2022-09-02, 15:32 authored by Tom Yates, Jack Sargeant, James KingJames King, Joe Henson, Charlotte Edwardson, Emma Redman, Gaurav Gulsin, Emer Brady, Ehtasham Ahmad, David StenselDavid Stensel, David Webb, Gerry McCann, Kamlesh Khunti, Melanie Davies

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.

RESEARCH DESIGN AND METHODS. We pooled data (n = 148) from three randomised trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison to sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies on accelerometer-assessed physical activity.

RESULTS: Liraglutide (-1144 steps/day; 95% CI -2069, -220), empagliflozin (-1132 steps/day; -1739, -524) and sitagliptin (-852 steps/day; -1625, -78) resulted in reduced total daily physical activity after 6 months (p< 0.01 vs. control). Moderate-to-vigorous intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.

CONCLUSIONS: The initiation of all glucose lowering therapies was associated with reduced physical activity, warranting further investigation.

Funding

The SEESAW trial was funded by an investigator-initiated grant from BoehringerIngelheim. The LYDIA trial was funded by an investigator-initiated grant from Novo Nordisk. The DIASTOLIC trial was funded by a grant from the National Institute for Health Research (CDF 2014-07-045)

National Institute for Health Research (NIHR) Leicester Biomedical Research Centre

History

School

  • Sport, Exercise and Health Sciences

Published in

Diabetes Care

Volume

45

Issue

11

Pages

2749-2752

Publisher

American Diabetes Association

Version

  • AM (Accepted Manuscript)

Rights holder

© American Diabetes Association

Publisher statement

This manuscript was accepted for publication in Diabetes Care on 26/07/2022. The final version of the paper is available on the Diabetes Care website at https://doi.org/10.2337/dc22-0888.

Acceptance date

2022-07-26

Publication date

2022-08-19

Copyright date

2022

ISSN

0149-5992

eISSN

1935-5548

Language

  • en

Depositor

Dr James King. Deposit date: 31 August 2022

Usage metrics

    Loughborough Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC